Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 2, 2022ToxinsOpen Access

OnabotulinumtoxinA Add-On to Monoclonal Anti-CGRP Antibodies in Treatment-Refractory Chronic Migraine

View Full Paper
Ask AI
Bookmark
Share

Authors

AAAndreas A. ArgyriouAgios Andreas HospitalEDEmmanouil V. Dermitzakis424 General Military HospitalGXGeorgia XiromerisiouUniversity of Thessaly

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Argyriou et al. (2022) studied this question.

synapsesocial.com/papers/6a0067e464548b97a42d8428https://doi.org/10.3390/toxins14120847
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Reliability of the Migraine Disability Assessment Score in A Population-Based Sample of Headache Sufferers1999 · 567 citations
  2. 2Treatment of Chronic Migraine with Erenumab Alone or as an Add on Therapy: A Real-World Observational Study2020 · 22 citations
  3. 3Extracranial injections of botulinum neurotoxin type A inhibit intracranial meningeal nociceptors’ responses to stimulation of TRPV1 and TRPA1 channels: Are we getting closer to solving this puzzle?2016 · 134 citations
  4. 4Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition2018 · 10,900 citations
  5. 5EQ-SD: a measure of health status from the EuroQol Group2001 · 5,755 citations